Dublin, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Research and Markets
(http://www.researchandmarkets.com/research/33dhcm/neuromodulation)
has announced the addition of the
"Neuromodulation Market - [Spinal Cord Stimulation (SCS), Vagus
Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep
Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), &
Transcranial Magnetic Stimulation (TMS)] - Forecasts to 2017"
report to their offering.
Neuromodulation devices have emerged as one of the fastest growing
segments of the medical device market due to high demand for
minimally invasive and non-invasive treatment. With advancements in
technology, neuromodulation is expected to become a promising
therapeutic area and high growth industry in the next decade, as it
offers symptomatic relief mainly from chronic pain, incontinence,
heart failure, headache, depression, epilepsy, etc. The
neuromodulation devices market includes deep brain stimulation,
spinal cord stimulation, vagus nerve stimulation, sacral nerve
stimulation and others external stimulation devices such as
transcranial magnetic stimulation, and transcutaneous electrical
nerve stimulation (TENS).
The neuromodulation technique acts directly upon nerves or the
target area where the activity of nerves is altered due to
biological responses produced by electrical stimulation or drug
infusion. These devices include small electrodes that are attached
to the brain, the spinal cord, or peripheral nerves. These
precisely placed leads are connected by means of an extension cable
to a pulse generator to generate electrical stimulation.
Neuromodulation can have applications in any area of the body and
can treat several diseases like chronic pain, epilepsy, psychiatric
disorder, movement disorder, cardiovascular disorder, genitourinary
and colorectal disorder, stroke and brain injury, and gastric
disorder.
The main drivers for the
neuromodulation market are the rising population of aged people
and age-related diseases like Alzheimer's, epilepsy, spinal cord
injury, and Parkinson's disease. According to the International
Neuromodulation Society, about 40 million to 50 million patients
worldwide suffer from epilepsy, and 1.5 million people currently
(2012) suffer from Parkinson disease in the U.S. The large pool of
patients that suffer from depression, stroke, anxiety disorders,
lower back pain, urinary incontinence, and tremor offers the
neuromodulation industry opportunities to grow in the next five
years. The market for treatment of tinnitus, in particular,
represents an emerging application of neuromodulation. According to
the American Tinnitus Association, about 50 million people
currently (2012) suffer from this disease in the U.S.
Key Topics Covered:
1 INTRODUCTION
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
4 GLOBAL NEUROMODULATION MARKET (INTERNAL & EXTERNAL)
5 GEOGRAPHIC ANALYSIS
6 COMPETITIVE LANDSCAPE
7 COMPANY PROFILES (Overview, Financials, Products & Services,
Strategy, & Developments)*
Companies Mentioned
- ANM ADAPTIVE NEUROMODULATION GMBH
- BIOCONTROL MEDICAL, LTD.
- BOSTON SCIENTIFIC CORPORATION
- CERBOMED GMBH
- CYBERONICS, INC.
- ENDOSTIM, INC.
- ENTEROMEDICS, INC.
- THE MAGSTIM COMPANY LIMITED
- MEDTRONIC, INC.
- NEURONETICS, INC.
- NEUROPACE, INC.
- NEUROSIGMA, INC.
- NEVRO CORPORATION
- RS MEDICAL
- SPINAL MODULATION, INC.
- ST. JUDE MEDICAL
- SYNAPSE BIOMEDICAL, INC.
- UROPLASTY, INC.
- ZYNEX, INC.
For more information visit http://www.researchandmarkets.com/research/33dhcm/neuromodulation
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector:
Medical Devices